Recombinant Human CXCL2/GRO beta (aa 39-107) Protein
R&D Systems, part of Bio-Techne | Catalog # 176-GB
Key Product Details
Product Specifications
Source
E. coli-derived human CXCL2/GRO beta/MIP-2/CINC-3 protein
Thr39-Asn107
Thr39-Asn107
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Thr39
Predicted Molecular Mass
7.5 kDa
Activity
Measured by its ability to induce myeloperoxidase release from cytochalasin B-treated human neutrophils. Schröder, J.M. et al. (1987) J. Immunol. 139:3474.
The ED50 for this effect is 0.1-0.3 µg/mL.
Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2.
The ED50 for this effect is 1-5 ng/mL.
The ED50 for this effect is 0.1-0.3 µg/mL.
Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2.
The ED50 for this effect is 1-5 ng/mL.
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 176-GB
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 176-GB/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CXCL2/GRO beta/MIP-2/CINC-3
Human GRO alpha, GRO beta (MIP-2 alpha), and GRO gamma (MIP-2 beta) are products of three distinct, non-allelic human genes. GRO beta and GRO gamma share 90% and 86% amino acid (aa) sequence homology, respectively, with GRO alpha. All three human GROs are members of the alpha (C-X-C) subfamily of chemokines and are thought to be the homologs of the murine KC, and MIP-2.
The three GRO cDNAs encode 107 aa precursor proteins from which the N-terminal 34 aa residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the aa sequences. GRO expression is inducible by serum, PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.
Similarly to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to CXCR2. The 69 aa variant of human GRO beta is approximately 3 times more active than the 73 aa variant (R&D Systems, Catalog # 276-GB) in inducing myeloperoxidase release from cytochalasin B treated neurotrophils.
References
- Chem. Immunol. (1999) 72:1.
Alternate Names
CINC-3, CINC3, GRO beta, MGSA-beta, MIP-2
Gene Symbol
CXCL2
UniProt
Additional CXCL2/GRO beta/MIP-2/CINC-3 Products
Product Documents for Recombinant Human CXCL2/GRO beta (aa 39-107) Protein
Product Specific Notices for Recombinant Human CXCL2/GRO beta (aa 39-107) Protein
For research use only
Loading...
Loading...
Loading...
Loading...